Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2025 08:45 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial

First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Patients Treated with Anti-Amyloid...
November 11, 2025 09:00 ET | Source: Gnome Sciences

Gnome Sciences Announces Cancer Drug Shows Promise in Stopping Progression of ALS

Gnome Sciences Discovers Cancer Drug Shows Promise in Stopping Progression of ALS. BCL2 inhibitors such as venetoclax may treat neurodegenerative diseases
October 21, 2025 08:44 ET | Source: Breakthrough Women in Science & Medicine

Breakthrough Women in Science & Medicine episode addresses the obesity epidemic — Premiering on PBS, November 1st

The November 1st episode addresses obesity misconceptions, the classification of obesity as a chronic disease, weight bias, and GLP-1s and surgery options.
September 23, 2025 00:30 ET | Source: Custom Market Insights

Global Health Intelligent Virtual Assistant Market Size/Share Worth USD 5643.4 Billion by 2034 at a 25.37% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Health Intelligent Virtual Assistant Market Size, Trends and Insights By...
August 11, 2025 09:00 ET | Source: Tiziana Life Sciences Ltd.

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
July 21, 2025 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
June 04, 2025 18:25 ET | Source: Foundation for Sarcoidosis Research

Foundation for Sarcoidosis Research Announces 2025 Global Virtual Sarcoidosis Summit – United for Progress: A New Chapter in Sarcoidosis

FSR Global Virtual Sarcoidosis Summit - June 28-29 - is the world’s largest online sarcoidosis event.
May 23, 2025 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
May 19, 2025 12:06 ET | Source: Foundation for Sarcoidosis Research

The Coalition to Transform Clinical Trial Engagement Launches National “Champions for Change – PTO Initiative” to Expand Access to Clinical Trials for Working Patients with 7 Corporate and Non-Profit Members

Coalition to Transform Clinical Trial Engagement (CTCTE) announces launch of Champions for Change – Paid Time Off (PTO) Initiative.
May 15, 2025 08:00 ET | Source: Tiziana Life Sciences Ltd.

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...